A5 LABORATORIES INCORPORATED (OTCBB: AFLB)
“Up 149.11% on Monday”
A5 Laboratories INC. (AFLB), a development stage company, focuses on providing contract research and laboratory services in North America. It specializes in the production of natural interferons using its gamma interferon production technology that allows producing interferons for the human and animal health market. The company plans to provide a range of analytical services to support a client’s quality control, product development, method development, validation, and marketed product activities; consulting and analytical services in chemistry, microbiology, and chromatography; and quality assurance and support services. It plans to offers its services to pharmaceutical companies, biotechnology companies, specialty pharmaceuticals, drug delivery companies, generics, and cosmetics industries. The company was formerly known as El Palenque Vivero, Inc. and changed its name to A5 Laboratories, Inc. in March 2010. A5 Laboratories, Inc. was founded in 2006 and is based in Lachina, Canada.
AFLB News:
June 28 - A5 Laboratories Announces Relocation of Facilities Into Biotechnology Research Institute in Montreal
A5 Laboratories Inc. (OTCBB: AFLB), a Biotechnology company by developing novel immune therapeutic applications of interferon therapy to treat cancer and infectious diseases, is pleased to announce the impending move of its cell culture and microbiology department of the C.R.O. division into the state-of-the-art facilities located in the Industrial Partnership Facility at the Biotechnology Research Institute in Montreal.
This move will hasten the development of A5 Laboratories’ proprietary methods for the production of animal interferon’s. The CRO division will aid A5 Labs in its clinical testing development while expanding its own client base in the areas of chemical analysis and microbiological testing.
The close proximity to renowned scientists in cell culture, protein purification, chemistry and biotechnology will allow A5 Labs to draw on this expertise as it moves toward commercialization of its products. Ready access to BRI’s specialized equipment and infrastructure will further enable this goal.
“We are excited about the move of our cell culture and microbiology department of the C.R.O. division into the state–of–art facilities at the Biotechnology Research Institute. The technology that will now be available to A5 Labs, will be a major step forward in the commercialization of A5 Labs products,” stated Dr. Richard Azani, president and CEO of A5 Laboratories.
If you find our information valuable, Subscribe to Strategic Stocks and Penny Stocks RSS Feed by e-mail, to Receive our Updates INSTANTLY, and share this post/page with your friends and followers with use of the Social Buttons.
Please read our Disclaimer regards to AFLB or any company reviewed or blogged about at Strategic Penny Stocks.
